Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 751Pancreatic Neoplasms 665Stomach Neoplasms 387Carcinoma, Non-Small-Cell Lung 375Carcinoma, Hepatocellular 368Breast Neoplasms 316Colonic Neoplasms 279Ovarian Neoplasms 260Neoplasms 250Esophageal Neoplasms 237Neoplasm Metastasis 215Rectal Neoplasms 202Melanoma 195Lung Neoplasms 193Liver Neoplasms 180Squamous Cell Carcinoma of Head and Neck 150Carcinoma, Renal Cell 146Head and Neck Neoplasms 124Prostatic Neoplasms 123Triple Negative Breast Neoplasms 109Uterine Cervical Neoplasms 106Urinary Bladder Neoplasms 106Cholangiocarcinoma 104Endometrial Neoplasms 101Sarcoma 99Small Cell Lung Carcinoma 74Gastrointestinal Neoplasms 73Esophageal Squamous Cell Carcinoma 68Kidney Neoplasms 63Carcinoma, Transitional Cell 60

Interventions

Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Cholangitis, Sclerosing × Gastrointestinal × Clear all
NCT00955149 2014-01-10

Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)

Mayo Clinic

Phase 1 Completed
6 enrolled
Gastrointestinal

Cholangitis, Sclerosing, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡